NCT05382741View on ClinicalTrials.gov

Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

PHASE2UnknownINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

March 2, 2024

Study Completion Date

March 2, 2024

Conditions
Colorectal Cancer Stage IVNo Evidence of Disease State
Interventions
DRUG

Durvalumab Injection for intravenous use 500 mg vial solution for infusion

MEDI4736

DRUG

Regorafenib 30 mg capsules

BAY73-4506

Trial Locations (1)

16132

RECRUITING

IRCCS Ospedale Policlinico San Martino, Genoa

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Associazione Italiana per la Ricerca sul Cancro

OTHER

collaborator

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

OTHER

collaborator

Bayer

INDUSTRY

lead

Ospedale Policlinico San Martino

OTHER